Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.

Coelho C, Dobbie LJ, Crane J, Douiri A, Learoyd AE, Okolo O, Panagiotopoulos S, Pournaras DJ, Ramar S, Rubino F, Singhal R, le Roux CW, Taheri S, McGowan B

International journal of obesity (2005)11 Sept 2023Cited by 12 (Europe PMC)

PMID37696925PMCIDPMC10599987DOI10.1038/s41366-023-01368-4PepBankPUB-37696925

Download PDF PubMedAsk about this study

Jump to 5 results

Summary

IntroductionObesity drives type 2 diabetes (T2DM) development. Laparoscopic adjustable gastric banding (LAGB) has lower weight reduction than other bariatric procedures. Liraglutide, a GLP-1 receptor agonist, improves weight and glycaemic control in patients with T2DM. This study aimed to determine the efficacy and safety of liraglutide 1.8 mg in participants undergoing LAGB.MethodsGLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1.8 mg or placebo in participants with T2DM and obesity. Participants were randomised (1:1) to 6-months therapy post-LAGB, with further 6 months off-treatment follow-up. The primary outcome was change in HbA1c from randomisation to the end of treatment, secondary outcomes included body weight change. A sample size of 58 (29 per group) had 80% power to detect a 0.6% difference in HbA1c between groups.ResultsTwenty-seven participants were randomised to liraglutide (n = 13) or placebo (n = 14). Multivariate analysis showed no difference between placebo and liraglutide arms in HbA1c at 6 months (HbA1c:0.2 mmol/mol, -11.3, 11.6, p = 0.98) however, at 12 months HbA1c was significantly higher in the liraglutide arm (HbA1c:10.9 mmol/mol, 1.1, 20.6, p = 0.032). There was no difference between arms in weight at 6 months (BW:2.0 kg, -4.2, 8.1, p = 0.50), however, at 12 months weight was significantly higher in the liraglutide arm (BW:8.2 kg, 1.6, 14.9, p = 0.02). There were no significant differences in adverse events between groups.ConclusionsOur pilot data suggest no additional improvement in glycaemic control or BW with LAGB and liraglutide therapy. However, this trial was significantly underpowered to detect a significant change in the primary or secondary outcomes. Further trials are needed to investigate whether GLP-1 agonists, and particularly with more effective weekly agents (i.e. semaglutide or tirzepatide), are of benefit following metabolic surgery.Clinical trial registrationEudraCT number 2015-005402-11.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and obesity after gastric banding, liraglutide 1.8 mg did not differ from placebo in HbA1c at 6 months.
In plain wordsIn adults with type 2 diabetes and obesity after gastric banding, liraglutide did not change HbA1c more than placebo after 6 months.
Peptide
Liraglutide
Outcome
No significant changeHbA1c difference at 6 months
Study
n = 27
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 6 monthsAs given in this study (human).
Measurements
HbA1c difference
0.2 mmol/mol
6 months
Source sentences
Summary
Multivariate analysis showed no difference between placebo and liraglutide arms in HbA1c at 6 months (HbA1c:0.2 mmol/mol, -11.3, 11.6, p = 0.98)
2 context sentences(design, population, supporting numbers)
Summary · context
GLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1.8 mg or placebo in participants with T2DM and obesity.
Summary · context
Twenty-seven participants were randomised to liraglutide (n = 13) or placebo (n = 14).
Show in the study text Report a problemFND-3769692501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and obesity after gastric banding, liraglutide 1.8 mg did not differ from placebo in body weight at 6 months.
In plain wordsIn adults with type 2 diabetes and obesity after gastric banding, liraglutide did not change weight more than placebo after 6 months.
Peptide
Liraglutide
Outcome
No significant changeBody weight difference at 6 months
Study
n = 27
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 6 monthsAs given in this study (human).
Measurements
body weight difference
2 kg
6 months
Source sentences
Summary
There was no difference between arms in weight at 6 months (BW:2.0 kg, -4.2, 8.1, p = 0.50)
2 context sentences(design, population, supporting numbers)
Summary · context
GLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1.8 mg or placebo in participants with T2DM and obesity.
Summary · context
Twenty-seven participants were randomised to liraglutide (n = 13) or placebo (n = 14).
Show in the study text Report a problemFND-3769692503
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and obesity after gastric banding, HbA1c was significantly higher in the liraglutide arm than in the placebo arm at 12 months, after 6 months off treatment.
In plain wordsIn adults with type 2 diabetes and obesity after gastric banding, HbA1c was higher in the liraglutide group than the placebo group at 12 months.
Peptide
Liraglutide
Outcome
IncreaseHbA1c difference at 12 months
Study
n = 27
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 6 monthsAs given in this study (human).
Measurements
HbA1c difference
10.9 mmol/mol
12 months
Source sentences
Summary
however, at 12 months HbA1c was significantly higher in the liraglutide arm (HbA1c:10.9 mmol/mol, 1.1, 20.6, p = 0.032).
2 context sentences(design, population, supporting numbers)
Summary · context
GLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1.8 mg or placebo in participants with T2DM and obesity.
Summary · context
Twenty-seven participants were randomised to liraglutide (n = 13) or placebo (n = 14).
Show in the study text Report a problemFND-3769692502
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and obesity after gastric banding, body weight was significantly higher in the liraglutide arm than in the placebo arm at 12 months, after 6 months off treatment.
In plain wordsIn adults with type 2 diabetes and obesity after gastric banding, weight was higher in the liraglutide group than the placebo group at 12 months.
Peptide
Liraglutide
Outcome
IncreaseBody weight difference at 12 months
Study
n = 27
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · 6 monthsAs given in this study (human).
Measurements
body weight difference
8.2 kg
12 months
Source sentences
Summary
however, at 12 months weight was significantly higher in the liraglutide arm (BW:8.2 kg, 1.6, 14.9, p = 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
GLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1.8 mg or placebo in participants with T2DM and obesity.
Summary · context
Twenty-seven participants were randomised to liraglutide (n = 13) or placebo (n = 14).
Show in the study text Report a problemFND-3769692504
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and obesity after gastric banding, adverse events did not differ significantly between the liraglutide and placebo groups.
In plain wordsIn adults with type 2 diabetes and obesity after gastric banding, side effects did not differ between liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeAdverse events
Study
n = 27
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
1.8 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no significant differences in adverse events between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
GLIDE, a pilot randomised, double-blind, placebo-controlled trial, evaluated LAGB with either liraglutide 1.8 mg or placebo in participants with T2DM and obesity.
Summary · context
Twenty-seven participants were randomised to liraglutide (n = 13) or placebo (n = 14).
Show in the study text Report a problemFND-3769692505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms